Low dose IL-2 increase regulatory T cells and elevate platelets in a patient with immune thrombocytopenia

How I treat refractory immune thrombocytopenia

(2016) A. Cuker et al.   BLOOD

Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial

(2015) Waleed Ghanima et al.   LANCET

Conditional IL-2 Gene Deletion: Consequences for T Cell Proliferation

(2012) Zoran Popmihajlov et al.   Frontiers in Immunology

Immunologic effects of rituximab on the human spleen in immune thrombocytopenia

(2011) S. Audia et al.   BLOOD

The Yin and Yang of Interleukin-2–Mediated Immunotherapy

(2011) Jeffrey A. Bluestone   NEW ENGLAND JOURNAL OF MEDICINE

Regulatory T-Cell Responses to Low-Dose Interleukin-2 in HCV-Induced Vasculitis

(2011) David Saadoun et al.   NEW ENGLAND JOURNAL OF MEDICINE

Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease

(2011) John Koreth et al.   NEW ENGLAND JOURNAL OF MEDICINE

Low-dose rituximab combined with short-term glucocorticoids up-regulates Treg cell levels in patients with immune thrombocytopenia

(2010) Zhenyu Li et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab

(2008) R. Stasi et al.   BLOOD

Recruitment of T cells into bone marrow of ITP patients possibly due to elevated expression of VLA-4 and CX3CR1

(2008) B. Olsson et al.   BLOOD